Article Text
PDF
Statistics from Altmetric.com
There are a number of inaccuracies in the article by D. Hunter, which the Health Research Authority (HRA) and Medicines and Healthcare Products Regulatory Agency (MHRA) in collaboration would like to take the opportunity to clarify.
The article refers to clinical trials being ‘highly regulated’ by research ethics committees (RECs), which is not strictly accurate. Clinical trials are regulated by the competent authority (in the UK, this is the MHRA). Clinical trials may only run once they have been authorised by the MHRA and receive a favourable ethical opinion from an REC. However, the issue of recruitment is an issue for the REC to consider when deciding whether to issue the favourable opinion.
D. Hunter states in the article that non-study-specific advertisements for phase 1 clinical trials fall into a regulatory loophole as they fall outside the requirement for review by an REC, as set out in the Association of the British Pharmaceutical Industry (ABPI) code of practice. This is not entirely accurate as the HRA, …
Footnotes
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Registration audit of clinical trials given a favourable opinion by UK research ethics committees
- UK regulator is to take lighter approach to drug advertisements
- The whistleblowing drama behind Astellas’s suspension from the ABPI
- Can an ethics officer role reduce delays in research ethics approval? A mixed-method evaluation of an improvement project
- Unethical pharmaceutical marketing: a common problem requiring collective responsibility
- Clinical trials: Streamlined framework aims to boost UK research
- Research ethics committee decision-making in relation to an efficient neonatal trial
- We could be heroes: ethical issues with the pre-recruitment of research participants
- Non-commercial clinical trials of a medicinal product: can they survive the current process of research approvals in the UK?
- New image for the drug industry